FBLG Financials

Income Statement
MetricQ2 2026Q1 2026Q4 2025Q3 2025Q2 2025
Revenue
0
0
0
0
0
Cost of Revenue
0
0
0
0
0
Gross Profit
0
0
0
0
0
Operating Expenses
4.0M
-20.4%
5.1M
+95.7%
2.6M
-48.6%
5.0M
+12.2%
4.5M
R&D
1.7M
-43.9%
3.0M
+270.5%
797.0K
-71.4%
2.8M
+36.6%
2.0M
SG&A
2.4M
+12.3%
2.1M
+18.0%
1.8M
-20.3%
2.2M
-8.2%
2.4M
Operating Income
-4033000
+20.4%
-5068000
-95.7%
-2590000
+48.6%
-5038000
-12.2%
-4490000
EBITDA
-3967000
+20.7%
-5002000
-158.4%
-1936000
+61.1%
-4973000
-12.3%
-4430000
Net Income
-4117000
+17.7%
-5000000
-54.1%
-3244000
+43.9%
-5778000
-24.0%
-4658000
EPS (Basic)
$-0.66
+50.4%
$-1.33
-171.4%
$-0.49
+81.2%
$-2.60
-7.9%
$-2.41
EPS (Diluted)
$-0.66
+50.4%
$-1.33
-171.4%
$-0.49
+81.2%
$-2.60
-7.9%
$-2.41
Shares (Diluted)
6.3M
+66.3%
3.8M
-42.7%
6.6M
+206.0%
2.2M
+11.5%
1.9M
FibroBiologics (FBLG) โ€” Financials